{"id":48362,"date":"2024-04-24T09:14:55","date_gmt":"2024-04-24T09:14:55","guid":{"rendered":"https:\/?p=48362"},"modified":"2024-04-24T09:14:55","modified_gmt":"2024-04-24T09:14:55","slug":"recursion-pharmaceuticals-a-deep-dive-into-the-ai-powered-biotech-company","status":"publish","type":"post","link":"https:\/\/www.stocktargetadvisor.com\/blog\/recursion-pharmaceuticals-a-deep-dive-into-the-ai-powered-biotech-company\/","title":{"rendered":"Recursion Pharmaceuticals: A Deep Dive into the AI-Powered Biotech Company"},"content":{"rendered":"<p><span style=\"font-weight: 400;\"><a href=\"https:\/\/www.stocktargetadvisor.com\/stock\/USA\/NSD\/RXRX\">Recursion Pharmaceuticals (RXRX: NSD)<\/a> is a biotech company pioneering the use of artificial intelligence (AI) to accelerate drug discovery. This innovative approach has the potential to revolutionize the pharmaceutical industry, but Recursion is a young company with no profits yet.<\/span><\/p>\n<p>&nbsp;<\/p>\n<h2><strong>Recursion Pharmaceuticals Investment: Pros and Cons:<\/strong><\/h2>\n<p><span style=\"font-weight: 400;\">Here are the benefits and risks of investing in the Recursion Pharma\u00a0<\/span><\/p>\n<p><b>Pros:<\/b><\/p>\n<ul>\n<li><span style=\"font-weight: 400;\">Recursion&#8217;s AI platform analyzes vast datasets to identify promising drug candidates, potentially leading to faster and more targeted treatments.<\/span><\/li>\n<li><span style=\"font-weight: 400;\">The company&#8217;s size offers some stability compared to smaller biotech firms.<\/span><\/li>\n<\/ul>\n<p><b>Cons:<\/b><\/p>\n<ul>\n<li><span style=\"font-weight: 400;\">Recursion has a history of significant losses and negative earnings growth.<\/span><\/li>\n<li><span style=\"font-weight: 400;\">The company is not yet profitable, and profitability may be years away.<\/span><\/li>\n<\/ul>\n<p>&nbsp;<\/p>\n<h2><strong>Stock Target Advisor\u2019s Analysis on Recursion Pharmaceuticals:<\/strong><\/h2>\n<p><span style=\"font-weight: 400;\">Stock Target Advisor has a &#8220;Strong Sell&#8221; rating for Recursion Pharmaceuticals due to factors like overpriced valuation and poor risk-adjusted returns. On the other hand, the covering analyst gives \u201cStrong Buy\u201d ratings to RXRX with the target price range of <\/span><span style=\"font-weight: 400;\">$14.60, <\/span><span style=\"font-weight: 400;\">indicating some disagreement on the company&#8217;s future value.<\/span><\/p>\n<p><!-- STA Widget BEGIN --><\/p>\n<div>\n<div class=\"sta-analyst-rating-widget-display\">\n<p><a style=\"text-decoration: none; color: #4b6db5 !important;\" href=\"https:\/\/www.stocktargetadvisor.com\/stock\/USA\/NSD\/RXRX\" target=\"_blank\" rel=\"noopener\">RXRX Ratings<\/a> by Stock Target Advisor<\/p>\n<\/div>\n<p><script class=\"analyst-rating\" type=\"text\/javascript\" src=\"https:\/\/www.stocktargetadvisor.com\/assets\/js\/analyst_rating_widget.js\" data-symbol=\"RXRX\" data-theme=\"wt_bg_trans\" data-uid=\"1541547336628c9bc626ec6628c9bc626ee\" data-width=\"700\" >\n\t\t<\/script><\/p>\n<\/div>\n<h2><strong>An Overview of Financial Performance:<\/strong><\/h2>\n<p><span style=\"font-weight: 400;\">Below are the key financial figures of <\/span><span style=\"font-weight: 400;\">Recursion Pharmaceuticals:<\/span><\/p>\n<p><b>Trailing 12 Months:<\/b><\/p>\n<ul>\n<li style=\"list-style-type: none;\">\n<ul>\n<li style=\"font-weight: 400;\" aria-level=\"2\"><span style=\"font-weight: 400;\">Revenue: $44.58 million<\/span><\/li>\n<li style=\"font-weight: 400;\" aria-level=\"2\"><span style=\"font-weight: 400;\">Net Loss: -$328.07 million<\/span><\/li>\n<li style=\"font-weight: 400;\" aria-level=\"2\"><span style=\"font-weight: 400;\">1-Year Capital Gain: 48.94% (outperforming sector)<\/span><\/li>\n<\/ul>\n<\/li>\n<\/ul>\n<p><b>Profitability Ratios:<\/b><\/p>\n<ul>\n<li style=\"list-style-type: none;\">\n<ul>\n<li style=\"list-style-type: none;\">\n<ul>\n<li style=\"font-weight: 400;\" aria-level=\"2\"><span style=\"font-weight: 400;\">Return on Assets (ROA): -32.29%<\/span><\/li>\n<li style=\"font-weight: 400;\" aria-level=\"2\"><span style=\"font-weight: 400;\">Return on Equity (ROE): -69.12%<\/span><\/li>\n<li style=\"font-weight: 400;\" aria-level=\"2\"><span style=\"font-weight: 400;\">Return on Invested Capital (ROIC): -72.76%<\/span><\/li>\n<\/ul>\n<\/li>\n<\/ul>\n<\/li>\n<\/ul>\n<p><b>Valuation Ratios:<\/b><\/p>\n<ul>\n<li style=\"list-style-type: none;\">\n<ul>\n<li style=\"font-weight: 400;\" aria-level=\"2\"><span style=\"font-weight: 400;\">Price to Book Ratio: 4.26 (higher than the sector average)<\/span><\/li>\n<li style=\"font-weight: 400;\" aria-level=\"2\"><span style=\"font-weight: 400;\">Price to Cash Flow Ratio: -5.99 (negative due to negative cash flow)<\/span><\/li>\n<\/ul>\n<\/li>\n<\/ul>\n<p>&nbsp;<\/p>\n<h2><strong>Conclusion:<\/strong><\/h2>\n<p><span style=\"font-weight: 400;\">Recursion Pharmaceuticals is a high-risk, high-reward investment opportunity. The company&#8217;s AI technology has the potential to disrupt the pharmaceutical industry, but significant uncertainty surrounds its future profitability.\u00a0<\/span><\/p>\n","protected":false},"excerpt":{"rendered":"<p>Recursion Pharmaceuticals (RXRX: NSD) is a biotech company pioneering the use of artificial intelligence (AI) to accelerate drug discovery. This innovative approach has the potential&#8230;<\/p>\n","protected":false},"author":17,"featured_media":48364,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"_acf_changed":false,"footnotes":""},"categories":[1],"tags":[],"class_list":["post-48362","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-blog"],"acf":[],"yoast_head":"<!-- This site is optimized with the Yoast SEO Premium plugin v19.4 (Yoast SEO v21.4) - https:\/\/yoast.com\/wordpress\/plugins\/seo\/ -->\n<title>Recursion Pharmaceuticals: A Deep Dive into the AI-Powered Biotech Company<\/title>\n<meta name=\"description\" content=\"Recursion Pharmaceuticals uses AI for drug discovery, but is it a profitable investment? Analysts are split. Read to learn more\" \/>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.stocktargetadvisor.com\/blog\/recursion-pharmaceuticals-a-deep-dive-into-the-ai-powered-biotech-company\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Recursion Pharmaceuticals: A Deep Dive into the AI-Powered Biotech Company\" \/>\n<meta property=\"og:description\" content=\"Recursion Pharmaceuticals uses AI for drug discovery, but is it a profitable investment? Analysts are split. Read to learn more\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.stocktargetadvisor.com\/blog\/recursion-pharmaceuticals-a-deep-dive-into-the-ai-powered-biotech-company\/\" \/>\n<meta property=\"og:site_name\" content=\"Stock Target Advisor\" \/>\n<meta property=\"article:publisher\" content=\"https:\/\/www.facebook.com\/StockTargetAdvisor\/\" \/>\n<meta property=\"article:published_time\" content=\"2024-04-24T09:14:55+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/www.stocktargetadvisor.com\/blog\/wp-content\/uploads\/2024\/04\/STAs-Blog-Images-3.png\" \/>\n\t<meta property=\"og:image:width\" content=\"1200\" \/>\n\t<meta property=\"og:image:height\" content=\"628\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/png\" \/>\n<meta name=\"author\" content=\"Muzzammil Ahmad\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:creator\" content=\"@https:\/\/x.com\/Muzzammil625\" \/>\n<meta name=\"twitter:site\" content=\"@AdvisorTarget\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Muzzammil Ahmad\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"2 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\/\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\/\/www.stocktargetadvisor.com\/blog\/recursion-pharmaceuticals-a-deep-dive-into-the-ai-powered-biotech-company\/#article\",\"isPartOf\":{\"@id\":\"https:\/\/www.stocktargetadvisor.com\/blog\/recursion-pharmaceuticals-a-deep-dive-into-the-ai-powered-biotech-company\/\"},\"author\":{\"name\":\"Muzzammil Ahmad\",\"@id\":\"https:\/\/www.stocktargetadvisor.com\/blog\/#\/schema\/person\/81d743c6903933055039390e1e98b5f8\"},\"headline\":\"Recursion Pharmaceuticals: A Deep Dive into the AI-Powered Biotech Company\",\"datePublished\":\"2024-04-24T09:14:55+00:00\",\"dateModified\":\"2024-04-24T09:14:55+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\/\/www.stocktargetadvisor.com\/blog\/recursion-pharmaceuticals-a-deep-dive-into-the-ai-powered-biotech-company\/\"},\"wordCount\":284,\"commentCount\":0,\"publisher\":{\"@id\":\"https:\/\/www.stocktargetadvisor.com\/blog\/#organization\"},\"articleSection\":[\"Market News &amp; Insights\"],\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"CommentAction\",\"name\":\"Comment\",\"target\":[\"https:\/\/www.stocktargetadvisor.com\/blog\/recursion-pharmaceuticals-a-deep-dive-into-the-ai-powered-biotech-company\/#respond\"]}]},{\"@type\":\"WebPage\",\"@id\":\"https:\/\/www.stocktargetadvisor.com\/blog\/recursion-pharmaceuticals-a-deep-dive-into-the-ai-powered-biotech-company\/\",\"url\":\"https:\/\/www.stocktargetadvisor.com\/blog\/recursion-pharmaceuticals-a-deep-dive-into-the-ai-powered-biotech-company\/\",\"name\":\"Recursion Pharmaceuticals: A Deep Dive into the AI-Powered Biotech Company\",\"isPartOf\":{\"@id\":\"https:\/\/www.stocktargetadvisor.com\/blog\/#website\"},\"datePublished\":\"2024-04-24T09:14:55+00:00\",\"dateModified\":\"2024-04-24T09:14:55+00:00\",\"description\":\"Recursion Pharmaceuticals uses AI for drug discovery, but is it a profitable investment? Analysts are split. Read to learn more\",\"breadcrumb\":{\"@id\":\"https:\/\/www.stocktargetadvisor.com\/blog\/recursion-pharmaceuticals-a-deep-dive-into-the-ai-powered-biotech-company\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\/\/www.stocktargetadvisor.com\/blog\/recursion-pharmaceuticals-a-deep-dive-into-the-ai-powered-biotech-company\/\"]}]},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\/\/www.stocktargetadvisor.com\/blog\/recursion-pharmaceuticals-a-deep-dive-into-the-ai-powered-biotech-company\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\/\/www.stocktargetadvisor.com\/blog\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Recursion Pharmaceuticals: A Deep Dive into the AI-Powered Biotech Company\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\/\/www.stocktargetadvisor.com\/blog\/#website\",\"url\":\"https:\/\/www.stocktargetadvisor.com\/blog\/\",\"name\":\"Stock Target Advisor\",\"description\":\"\",\"publisher\":{\"@id\":\"https:\/\/www.stocktargetadvisor.com\/blog\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\/\/www.stocktargetadvisor.com\/blog\/?s={search_term_string}\"},\"query-input\":\"required name=search_term_string\"}],\"inLanguage\":\"en-US\"},{\"@type\":\"Organization\",\"@id\":\"https:\/\/www.stocktargetadvisor.com\/blog\/#organization\",\"name\":\"Stock Target Advisor\",\"alternateName\":\"STA\",\"url\":\"https:\/\/www.stocktargetadvisor.com\/blog\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\/\/www.stocktargetadvisor.com\/blog\/#\/schema\/logo\/image\/\",\"url\":\"http:\/\/stocktargetadvisor.com\/wp-content\/uploads\/2019\/10\/STAlogo.jpeg\",\"contentUrl\":\"http:\/\/stocktargetadvisor.com\/wp-content\/uploads\/2019\/10\/STAlogo.jpeg\",\"width\":\"225\",\"height\":\"225\",\"caption\":\"Stock Target Advisor\"},\"image\":{\"@id\":\"https:\/\/www.stocktargetadvisor.com\/blog\/#\/schema\/logo\/image\/\"},\"sameAs\":[\"https:\/\/www.facebook.com\/StockTargetAdvisor\/\",\"https:\/\/twitter.com\/AdvisorTarget\"]},{\"@type\":\"Person\",\"@id\":\"https:\/\/www.stocktargetadvisor.com\/blog\/#\/schema\/person\/81d743c6903933055039390e1e98b5f8\",\"name\":\"Muzzammil Ahmad\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\/\/www.stocktargetadvisor.com\/blog\/#\/schema\/person\/image\/\",\"url\":\"https:\/\/secure.gravatar.com\/avatar\/d361e040abeba4e5b47d2fb7acae1401555042a5fc6862b11d7d01ac1722fed5?s=96&d=mm&r=g\",\"contentUrl\":\"https:\/\/secure.gravatar.com\/avatar\/d361e040abeba4e5b47d2fb7acae1401555042a5fc6862b11d7d01ac1722fed5?s=96&d=mm&r=g\",\"caption\":\"Muzzammil Ahmad\"},\"description\":\"Muzzammil is a content writer at Stock Target Advisor. He has been writing stock news and analysis at Stock Target Advisor since 2023 and has worked in the financial domain in various roles since 2020. He has previously worked on an equity research firm that analyzed companies listed on the stock markets in the U.S. and Canada and performed fundamental and qualitative analyses of management strength, business strategy, and product\/services forecast as indicated by major brokers covering the stock.\",\"sameAs\":[\"https:\/\/www.linkedin.com\/in\/muzzammil-ahmad-a157b1190\/\",\"https:\/\/twitter.com\/https:\/\/x.com\/Muzzammil625\"],\"url\":\"https:\/\/www.stocktargetadvisor.com\/blog\/author\/muzzammil\/\"}]}<\/script>\n<!-- \/ Yoast SEO Premium plugin. -->","yoast_head_json":{"title":"Recursion Pharmaceuticals: A Deep Dive into the AI-Powered Biotech Company","description":"Recursion Pharmaceuticals uses AI for drug discovery, but is it a profitable investment? Analysts are split. Read to learn more","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.stocktargetadvisor.com\/blog\/recursion-pharmaceuticals-a-deep-dive-into-the-ai-powered-biotech-company\/","og_locale":"en_US","og_type":"article","og_title":"Recursion Pharmaceuticals: A Deep Dive into the AI-Powered Biotech Company","og_description":"Recursion Pharmaceuticals uses AI for drug discovery, but is it a profitable investment? Analysts are split. Read to learn more","og_url":"https:\/\/www.stocktargetadvisor.com\/blog\/recursion-pharmaceuticals-a-deep-dive-into-the-ai-powered-biotech-company\/","og_site_name":"Stock Target Advisor","article_publisher":"https:\/\/www.facebook.com\/StockTargetAdvisor\/","article_published_time":"2024-04-24T09:14:55+00:00","og_image":[{"width":1200,"height":628,"url":"https:\/\/www.stocktargetadvisor.com\/blog\/wp-content\/uploads\/2024\/04\/STAs-Blog-Images-3.png","type":"image\/png"}],"author":"Muzzammil Ahmad","twitter_card":"summary_large_image","twitter_creator":"@https:\/\/x.com\/Muzzammil625","twitter_site":"@AdvisorTarget","twitter_misc":{"Written by":"Muzzammil Ahmad","Est. reading time":"2 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/www.stocktargetadvisor.com\/blog\/recursion-pharmaceuticals-a-deep-dive-into-the-ai-powered-biotech-company\/#article","isPartOf":{"@id":"https:\/\/www.stocktargetadvisor.com\/blog\/recursion-pharmaceuticals-a-deep-dive-into-the-ai-powered-biotech-company\/"},"author":{"name":"Muzzammil Ahmad","@id":"https:\/\/www.stocktargetadvisor.com\/blog\/#\/schema\/person\/81d743c6903933055039390e1e98b5f8"},"headline":"Recursion Pharmaceuticals: A Deep Dive into the AI-Powered Biotech Company","datePublished":"2024-04-24T09:14:55+00:00","dateModified":"2024-04-24T09:14:55+00:00","mainEntityOfPage":{"@id":"https:\/\/www.stocktargetadvisor.com\/blog\/recursion-pharmaceuticals-a-deep-dive-into-the-ai-powered-biotech-company\/"},"wordCount":284,"commentCount":0,"publisher":{"@id":"https:\/\/www.stocktargetadvisor.com\/blog\/#organization"},"articleSection":["Market News &amp; Insights"],"inLanguage":"en-US","potentialAction":[{"@type":"CommentAction","name":"Comment","target":["https:\/\/www.stocktargetadvisor.com\/blog\/recursion-pharmaceuticals-a-deep-dive-into-the-ai-powered-biotech-company\/#respond"]}]},{"@type":"WebPage","@id":"https:\/\/www.stocktargetadvisor.com\/blog\/recursion-pharmaceuticals-a-deep-dive-into-the-ai-powered-biotech-company\/","url":"https:\/\/www.stocktargetadvisor.com\/blog\/recursion-pharmaceuticals-a-deep-dive-into-the-ai-powered-biotech-company\/","name":"Recursion Pharmaceuticals: A Deep Dive into the AI-Powered Biotech Company","isPartOf":{"@id":"https:\/\/www.stocktargetadvisor.com\/blog\/#website"},"datePublished":"2024-04-24T09:14:55+00:00","dateModified":"2024-04-24T09:14:55+00:00","description":"Recursion Pharmaceuticals uses AI for drug discovery, but is it a profitable investment? Analysts are split. Read to learn more","breadcrumb":{"@id":"https:\/\/www.stocktargetadvisor.com\/blog\/recursion-pharmaceuticals-a-deep-dive-into-the-ai-powered-biotech-company\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.stocktargetadvisor.com\/blog\/recursion-pharmaceuticals-a-deep-dive-into-the-ai-powered-biotech-company\/"]}]},{"@type":"BreadcrumbList","@id":"https:\/\/www.stocktargetadvisor.com\/blog\/recursion-pharmaceuticals-a-deep-dive-into-the-ai-powered-biotech-company\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/www.stocktargetadvisor.com\/blog\/"},{"@type":"ListItem","position":2,"name":"Recursion Pharmaceuticals: A Deep Dive into the AI-Powered Biotech Company"}]},{"@type":"WebSite","@id":"https:\/\/www.stocktargetadvisor.com\/blog\/#website","url":"https:\/\/www.stocktargetadvisor.com\/blog\/","name":"Stock Target Advisor","description":"","publisher":{"@id":"https:\/\/www.stocktargetadvisor.com\/blog\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.stocktargetadvisor.com\/blog\/?s={search_term_string}"},"query-input":"required name=search_term_string"}],"inLanguage":"en-US"},{"@type":"Organization","@id":"https:\/\/www.stocktargetadvisor.com\/blog\/#organization","name":"Stock Target Advisor","alternateName":"STA","url":"https:\/\/www.stocktargetadvisor.com\/blog\/","logo":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.stocktargetadvisor.com\/blog\/#\/schema\/logo\/image\/","url":"http:\/\/stocktargetadvisor.com\/wp-content\/uploads\/2019\/10\/STAlogo.jpeg","contentUrl":"http:\/\/stocktargetadvisor.com\/wp-content\/uploads\/2019\/10\/STAlogo.jpeg","width":"225","height":"225","caption":"Stock Target Advisor"},"image":{"@id":"https:\/\/www.stocktargetadvisor.com\/blog\/#\/schema\/logo\/image\/"},"sameAs":["https:\/\/www.facebook.com\/StockTargetAdvisor\/","https:\/\/twitter.com\/AdvisorTarget"]},{"@type":"Person","@id":"https:\/\/www.stocktargetadvisor.com\/blog\/#\/schema\/person\/81d743c6903933055039390e1e98b5f8","name":"Muzzammil Ahmad","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.stocktargetadvisor.com\/blog\/#\/schema\/person\/image\/","url":"https:\/\/secure.gravatar.com\/avatar\/d361e040abeba4e5b47d2fb7acae1401555042a5fc6862b11d7d01ac1722fed5?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/d361e040abeba4e5b47d2fb7acae1401555042a5fc6862b11d7d01ac1722fed5?s=96&d=mm&r=g","caption":"Muzzammil Ahmad"},"description":"Muzzammil is a content writer at Stock Target Advisor. He has been writing stock news and analysis at Stock Target Advisor since 2023 and has worked in the financial domain in various roles since 2020. He has previously worked on an equity research firm that analyzed companies listed on the stock markets in the U.S. and Canada and performed fundamental and qualitative analyses of management strength, business strategy, and product\/services forecast as indicated by major brokers covering the stock.","sameAs":["https:\/\/www.linkedin.com\/in\/muzzammil-ahmad-a157b1190\/","https:\/\/twitter.com\/https:\/\/x.com\/Muzzammil625"],"url":"https:\/\/www.stocktargetadvisor.com\/blog\/author\/muzzammil\/"}]}},"_links":{"self":[{"href":"https:\/\/www.stocktargetadvisor.com\/blog\/wp-json\/wp\/v2\/posts\/48362","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.stocktargetadvisor.com\/blog\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.stocktargetadvisor.com\/blog\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.stocktargetadvisor.com\/blog\/wp-json\/wp\/v2\/users\/17"}],"replies":[{"embeddable":true,"href":"https:\/\/www.stocktargetadvisor.com\/blog\/wp-json\/wp\/v2\/comments?post=48362"}],"version-history":[{"count":1,"href":"https:\/\/www.stocktargetadvisor.com\/blog\/wp-json\/wp\/v2\/posts\/48362\/revisions"}],"predecessor-version":[{"id":48365,"href":"https:\/\/www.stocktargetadvisor.com\/blog\/wp-json\/wp\/v2\/posts\/48362\/revisions\/48365"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/www.stocktargetadvisor.com\/blog\/wp-json\/wp\/v2\/media\/48364"}],"wp:attachment":[{"href":"https:\/\/www.stocktargetadvisor.com\/blog\/wp-json\/wp\/v2\/media?parent=48362"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.stocktargetadvisor.com\/blog\/wp-json\/wp\/v2\/categories?post=48362"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.stocktargetadvisor.com\/blog\/wp-json\/wp\/v2\/tags?post=48362"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}